EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 541 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Improving Cancer Immunotherapy: Overcoming the Problem of ‘Exhausted’ T Cells July 18, 2019 From Scan to Scan: The Challenges of Living with Metastatic Cancer October 15, 2021 Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer June 12, 2020 ‘From virtual reality tumours to cutting-edge treatments’: what to expect from... May 23, 2022 Load more HOT NEWS 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... Benefits of Regular Breast Cancer Screening Outweigh Risks of Overdiagnosis, New... Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar... Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer
